UroGen Pharma Net Worth
UroGen Pharma Net Worth Breakdown | URGN |
UroGen Pharma Net Worth Analysis
UroGen Pharma's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including UroGen Pharma's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of UroGen Pharma's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform UroGen Pharma's net worth analysis. One common approach is to calculate UroGen Pharma's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares UroGen Pharma's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing UroGen Pharma's net worth. This approach calculates the present value of UroGen Pharma's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of UroGen Pharma's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate UroGen Pharma's net worth. This involves comparing UroGen Pharma's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into UroGen Pharma's net worth relative to its peers.
Enterprise Value |
|
To determine if UroGen Pharma is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding UroGen Pharma's net worth research are outlined below:
| UroGen Pharma generated a negative expected return over the last 90 days | |
| UroGen Pharma has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 82.71 M. Net Loss for the year was (102.24 M) with profit before overhead, payroll, taxes, and interest of 80.67 M. | |
| UroGen Pharma currently holds about 111.74 M in cash with (76.38 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.91. | |
| Over 92.0% of the company outstanding shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Acquisition by Degnan Chris of 13450 shares of UroGen Pharma subject to Rule 16b-3 |
UroGen Pharma uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in UroGen Pharma. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to UroGen Pharma's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 9th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Follow UroGen Pharma's market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 478.96 M.Market Cap |
|
Project UroGen Pharma's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.52) | (0.54) | |
| Return On Capital Employed | (0.40) | (0.42) | |
| Return On Assets | (0.52) | (0.54) | |
| Return On Equity | 1.80 | 1.89 |
When accessing UroGen Pharma's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures UroGen Pharma's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of UroGen Pharma's profitability and make more informed investment decisions.
Evaluate UroGen Pharma's management efficiency
UroGen Pharma has return on total asset (ROA) of (0.2112) % which means that it has lost $0.2112 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (14.8126) %, meaning that it created substantial loss on money invested by shareholders. UroGen Pharma's management efficiency ratios could be used to measure how well UroGen Pharma manages its routine affairs as well as how well it operates its assets and liabilities. As of the 31st of January 2025, Return On Equity is likely to grow to 1.89, while Return On Tangible Assets are likely to drop (0.54). At this time, UroGen Pharma's Total Assets are very stable compared to the past year. As of the 31st of January 2025, Other Current Assets is likely to grow to about 13.4 M, though Net Tangible Assets are likely to grow to (97.6 M).| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (2.60) | (2.47) | |
| Tangible Book Value Per Share | (2.60) | (2.47) | |
| Enterprise Value Over EBITDA | (7.89) | (7.49) | |
| Price Book Value Ratio | (7.63) | (7.25) | |
| Enterprise Value Multiple | (7.89) | (7.49) | |
| Price Fair Value | (7.63) | (7.25) | |
| Enterprise Value | 221.4 M | 197.9 M |
At UroGen Pharma, effective management practices are pivotal to sustaining long-term profitability. We delve into financial metrics and market conditions to provide a comprehensive analysis of the stock's prospects.
Enterprise Value Revenue 3.9313 | Revenue | Quarterly Revenue Growth 0.209 | Revenue Per Share | Return On Equity |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific UroGen Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on UroGen Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases UroGen Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
UroGen Pharma Corporate Filings
8K | 14th of January 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F3 | 18th of November 2024 An amendment to the original Schedule 13D filing | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
13A | 12th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
UroGen Pharma Earnings per Share Projection vs Actual
UroGen Pharma Corporate Management
| Dong Kim | Chief Officer | Profile | |
| Jason JD | Chief Counsel | Profile | |
| Sari PrutchiSagiv | Marketing Director | Profile | |
| Jason Smith | Chief Counsel | Profile | |
| Bryon Wornson | Advocacy Talent | Profile | |
| Eric Zanten | Director Communications | Profile | |
| Christopher CPA | Chief Officer | Profile |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in UroGen Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price. To learn how to invest in UroGen Stock, please use our How to Invest in UroGen Pharma guide.You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of UroGen Pharma. If investors know UroGen will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about UroGen Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.02) | Revenue Per Share | Quarterly Revenue Growth 0.209 | Return On Assets | Return On Equity |
The market value of UroGen Pharma is measured differently than its book value, which is the value of UroGen that is recorded on the company's balance sheet. Investors also form their own opinion of UroGen Pharma's value that differs from its market value or its book value, called intrinsic value, which is UroGen Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because UroGen Pharma's market value can be influenced by many factors that don't directly affect UroGen Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between UroGen Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if UroGen Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, UroGen Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.